Inclusion Criteria:  Male or non-pregnant female adults, ≥18 years old of age at the time of randomization; Participants should have at least one of COVID-19 risk factor; Participants should have at least 2 COVID-19 related symptoms; Has symptoms consistent with COVID-19 as determined by the investigator with onset ≤10 days before randomization; First positive SARS-CoV-2 viral infection tested (PCR or antigen-based diagnostic tests) in samples collected ≤5 days prior to start of the infusion;  Exclusion Criteria:  Participants with a history of severe anaphylaxis, such as severe anaphylactic reaction, urticaria, and angioedema; Have SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 < 300, respiratory rate ≥30 per minute, heart rate ≥125 per minute (FDA); Require mechanical ventilation or anticipated impending need for mechanical ventilation; Suspected or proven serious bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking part in this study; Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study;